What is Locus Biosciences?
Locus Biosciences is a clinical-stage biotechnology enterprise headquartered in Morrisville, North Carolina. Founded in 2015, the company specializes in the development of precision medicines designed to address unmet needs in infectious and inflammatory disease sectors. By utilizing advanced engineering techniques, Locus Biosciences aims to transform the standard of care through targeted therapeutic interventions. The firm occupies a strategic position at the intersection of life sciences and data-driven innovation, focusing on scalable medical technologies that leverage sophisticated biological platforms to improve patient outcomes globally.
How much funding has Locus Biosciences raised?
Locus Biosciences has raised a total of $85.3M across 5 funding rounds:
Private Equity
$1.3M
Angel/Seed
$5M
Series A
$19M
Debt
$25M
Series B
$35M
Private Equity (2016): $1.3M, investors not publicly disclosed
Angel/Seed (2017): $5M led by North Carolina Biotechnology Center and Tencent
Series A (2017): $19M supported by Artis Ventures, Tencent, North Carolina Biotechnology Center, and Abstract Ventures
Debt (2021): $25M featuring Hercules Capital
Series B (2022): $35M backed by Johnson & Johnson Innovation, Artis Ventures Management Iii, Tencent, and Viking Global Investors
Key Investors in Locus Biosciences
Tencent
Tencent is a global technology conglomerate that invests in innovation across digital platforms, cloud computing, and artificial intelligence to support developers and drive international market growth.
North Carolina Biotechnology Center
NCBiotech is a premier life science economic development organization dedicated to transforming research into marketable products and advancing North Carolina's position as a global biotech leader.
Viking Global Investors
Viking Global Investors is a research-intensive investment firm that utilizes fundamental analysis to select high-potential public and private equity interests across diverse global industries.
What's next for Locus Biosciences?
With the recent influx of capital, Locus Biosciences is poised to enter a pivotal phase of clinical expansion. The strategic roadmap likely involves intensifying research and development efforts to validate its therapeutic candidates in human trials. Furthermore, the company is expected to strengthen its intellectual property portfolio and deepen its collaborative network with global healthcare partners. As it moves forward, the focus will remain on operational excellence and the systematic de-risking of its pipeline, ensuring that its precision medicine innovations can effectively navigate the regulatory landscape and reach the market to address critical public health challenges.
See full Locus Biosciences company page
